ArticleCurrent oncology (Toronto, Ont.)2020
Canadian consensus: a new systemic treatment algorithm for advanced
Article in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.Current oncology (Toronto, Ont.) · 2026Review
- Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta.Current oncology (Toronto, Ont.) · 2024Article
- Real-World Treatment Patterns and Survival Among Patients with Stage I-III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment.Oncology and therapy · 2024Article
- Real-World Analysis of Post-Progression Treatment Patterns and Outcomes forCurrent oncology (Toronto, Ont.) · 2024Article
- Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.Current oncology (Toronto, Ont.) · 2024Article
- Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform.Current oncology (Toronto, Ont.) · 2022Article
- Prevalence, Treatment Patterns, and Outcomes of Individuals withCurrent oncology (Toronto, Ont.) · 2022Article
- The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer.The patient · 2022Article
- EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report.Current oncology (Toronto, Ont.) · 2022Article
- Intracranial Metastatic Disease: Present Challenges, Future Opportunities.Frontiers in oncology · 2022Review
- Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.Current oncology (Toronto, Ont.) · 2021Article
- Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study.World journal of surgical oncology · 2021Article
- Consensus recommendations for optimizing biomarker testing to identify and treat advancedCurrent oncology (Toronto, Ont.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple clinical trials for the treatment of advanced Methods: A Canadian expert panel was convened to define the key clinical questions, review recent evidence, and discuss and agree on practice recommendations for the treatment of advanced Results: The published overall survival results for osimertinib, combined with its central nervous system activity, have led to osimertinib becoming the preferred first-line treatment for patients with common Conclusions: This Canadian expert consensus statement and algorithm were driven by significant advances in the treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.